Form D · Biotechnology
Aethon Therapeutics, Inc.
New York, NY · CIK 0001958956
Offering snapshot reported Dec 22, 2022 · SEC filing
- Reported sold
- $6M Offering amount: $30M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 16, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 22, 2022 | Initial | $6,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-468421
Source: Form D, filed Dec 22, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rajesh Chopra | Director, Executive |
| Paul Da Silva Jardine | Director, Executive |
| William Engels | Executive |
| Seth Harrison | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
230 Park Avenue Suite 2800
New York, NY, 10169
New York, NY, 10169